Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

被引:885
作者
Morgan, Richard A. [1 ]
Chinnasamy, Nachimuthu [1 ]
Abate-Daga, Daniel [1 ]
Gros, Alena [1 ]
Robbins, Paul F. [1 ]
Zheng, Zhili [1 ]
Dudley, Mark E. [1 ]
Feldman, Steven A. [1 ]
Yang, James C. [1 ]
Sherry, Richard M. [1 ]
Phan, Giao Q. [1 ]
Hughes, Marybeth S. [1 ]
Kammula, Udai S. [1 ]
Miller, Akemi D. [1 ]
Hessman, Crystal J. [1 ]
Stewart, Ashley A. [1 ]
Restifo, Nicholas P. [1 ]
Quezado, Martha M. [2 ]
Alimchandani, Meghna [2 ]
Rosenberg, Avi Z. [2 ]
Nath, Avindra [3 ]
Wang, Tongguang [3 ]
Bielekova, Bibiana [3 ]
Wuest, Simone C. [3 ]
Akula, Nirmala [4 ]
McMahon, Francis J. [4 ]
Wilde, Susanne [5 ]
Mosetter, Barbara [5 ]
Schendel, Dolores J. [5 ,6 ]
Laurencot, Carolyn M. [1 ]
Rosenberg, Steven A. [1 ]
机构
[1] NCI, Surg Branch, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, Bethesda, MD 20892 USA
[3] NINDS, Neuroimmunol Branch, Bethesda, MD 20892 USA
[4] NIMH, Human Genet Branch, Bethesda, MD 20892 USA
[5] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Mol Immunol, Munich, Germany
[6] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Clin Cooperat Grp Immune Monitoring, Munich, Germany
关键词
cancer-testes antigen; immunotherapy; TCR; gene therapy; INFLAMMATORY DEMYELINATING POLYNEUROPATHY; MAGE-A FAMILY; METASTATIC MELANOMA; CANCER/TESTIS ANTIGENS; PROSTATE-CANCER; ADVERSE EVENT; HIGH AVIDITY; CELLS; EXPRESSION; TARGETS;
D O I
10.1097/CJI.0b013e3182829903
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nine cancer patients were treated with adoptive cell therapy using autologous anti-MAGE-A3 T-cell receptors (TCR)engineered T cells. Five patients experienced clinical regression of their cancers including 2 on-going responders. Beginning 1-2 days postinfusion, 3 patients (#'s 5, 7, and 8) experienced mental status changes, and 2 patients (5 and 8) lapsed into comas and subsequently died. Magnetic resonance imagining analysis of patients 5 and 8 demonstrated periventricular leukomalacia, and examination of their brains at autopsy revealed necrotizing leukoence-phalopathy with extensive white matter defects associated with infiltration of CD3(+) /CD8(+) T cells. Patient 7, developed Parkinson- like symptoms, which resolved over 4 weeks and fully recovered. Immunohistochemical staining of patient and normal brain samples demonstrated rare positively staining neurons with an antibody that recognizes multiple MAGE-A family members. The TCR used in this study recognized epitopes in MAGE-A3/A9/A12. Molecular assays of human brain samples using real-time quantitative-polymerase chain reaction, Nanostring quantitation, and deep-sequencing indicated that MAGE-A12 was expressed in human brain (and possibly MAGE-A1, MAGE-A8, and MAGEA9). This previously unrecognized expression of MAGE-A12 in human brain was possibly the initiating event of a TCR-mediated inflammatory response that resulted in neuronal cell destruction and raises caution for clinical applications targeting MAGE-A family members with highly active immunotherapies.
引用
收藏
页码:133 / 151
页数:19
相关论文
共 71 条
[1]   Altered Differentiation, Diminished Pathogenicity, and Regulatory Activity of Myelin-Specific T Cells Expressing an Enhanced Affinity TCR [J].
Alli, Rajshekhar ;
Phuong Nguyen ;
Geiger, Terrence L. .
JOURNAL OF IMMUNOLOGY, 2011, 187 (11) :5521-5531
[2]   Evolution of the exon-intron structure and alternative splicing of the MAGE-A family of cancer/testis antigens [J].
Artamonova, II ;
Gelfand, MS .
JOURNAL OF MOLECULAR EVOLUTION, 2004, 59 (05) :620-631
[3]   Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming [J].
Atanackovic, Djordje ;
Altorki, Nasser K. ;
Cao, Yanran ;
Ritter, Erika ;
Ferrara, Cathy A. ;
Ritter, Gerd ;
Hoffman, Eric W. ;
Bokemeyer, Carsten ;
Old, Lloyd J. ;
Gnjatic, Sacha .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (05) :1650-1655
[4]   High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer [J].
Bergeron, Alain ;
Picard, Valerie ;
LaRue, Helene ;
Harel, Francois ;
Hovington, Helene ;
Lacombe, Louis ;
Fradet, Yves .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (06) :1365-1371
[5]   Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis [J].
Bielekova, B ;
Catalfamo, M ;
Reichert-Scrivner, S ;
Packer, A ;
Cerna, M ;
Waldmann, TA ;
McFarland, H ;
Henkart, PA ;
Martin, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) :5941-5946
[6]   Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma [J].
Bird, SJ ;
Brown, MJ ;
Shy, ME ;
Scherer, SS .
NEUROLOGY, 1996, 46 (03) :822-824
[7]   Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial [J].
Brentjens, Renier ;
Yeh, Raymond ;
Bernal, Yvette ;
Riviere, Isabelle ;
Sadelain, Michel .
MOLECULAR THERAPY, 2010, 18 (04) :666-668
[8]   Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease [J].
Brichard, Vincent G. ;
Lejeune, Diane .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (07) :951-968
[9]   GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development [J].
Brichard, Vincent G. ;
Lejeune, Diane .
VACCINE, 2007, 25 :B61-B71
[10]   Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis [J].
Brucklacher-Waldert, Verena ;
Sturner, Klarissa ;
Kolster, Manuela ;
Wolthausen, Julia ;
Tolosa, Eva .
BRAIN, 2009, 132 :3329-3341